Clin2
NCT06592014Possibly a fitEnrolling by invitation

Lithium for Parkinson's: an extension trial

Parkinson Disease

Part of Brain & nervous system clinical trials.

This trial extends a previous study to see if lithium can help Parkinson's symptoms. It's for people who already took part in a related study at the University at Buffalo.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
35 people
Ages
45 years to 80 years
Study type
Interventional

Who can take part

  • You must have completed one of the earlier Parkinson's studies (STUDY00007253 or STUDY00008239) at the University at Buffalo.
  • No unstable heart, medical, nerve (like Parkinson's itself), or mental health problems that the study doctor thinks could be unsafe.
  • No current use of illegal drugs or alcohol abuse as judged by the study doctor.
  • No past brain surgery or need for brain surgery (including deep brain stimulation) within the next 24 weeks.
  • If you can become pregnant, you need a negative pregnancy test and must use birth control (barrier method or hormonal).
  • You must be willing to sign a consent form and follow the study's rules.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06466525Recruiting· Phase 1
Testing LBT-3627 for safety in healthy adults and people with Parkinson's

This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.

Melbourne, Victoria
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT07280299Not yet recruiting· Phase 2
Study of a new medicine for early Parkinson's disease

This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.

NCT06344026Enrolling by invitation· Phase 1
A cell therapy trial for Parkinson's disease

This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.

Tucson, Arizona
NCT05266872Recruiting
Earlier diagnosis and better treatment study for Parkinson’s

This study is looking to improve how Parkinson’s and related brain conditions are identified and treated sooner. You may be asked to share your health information and provide blood or other samples, and possibly have procedures like a spinal fluid test or a small skin sample.

Luxembourg
NCT07732933Not yet recruiting
Testing a new lithium delivery method for bipolar disorder

This study tests a new way to deliver lithium, a common treatment for bipolar disorder, using tiny gold particles. It aims to see if this method is safe and effective in laboratory models, which may lead to better treatments with fewer side effects.

Roma

Hear when a new Parkinson Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.